SEBI v. Concord Drugs Ltd and others (misstated financials, 2023)

Judgment entered

✓ Checked against the primary document on October 8, 2026. The library's summary, tags and figures for this record were compared with the regulator's own document by an AI model (Claude) following written instructions, in a single reading of the order; an independent second reading of 60 SEBI records agreed on every field for 56, the four misses being penalty amounts; a later sample of 50 of the SEBI records added on 9 October agreed on every field for 46. No lawyer has reviewed them. A checked record can still contain errors, and checked does not mean endorsed. See how we check records or report a correction.

Report an error in this record (sebi-75237-misleading-issuer-disclosure-2023) by email

On 11 August 2023 a SEBI adjudicating officer found that Concord Drugs misrepresented its financial statements for 2015-20, including non-disclosure of related parties, and penalised the company and eleven officers a combined Rs 1,07,00,000. The case began with a complaint about discrepancies in the company's trade receivables.

The record

What was ordered

Civil penalty

—

Disgorgement

—

Prejudgment interest

—

Total relief

—

Alleged gain

—

Penalty as published

10.7m INR

A dash means the release did not state a figure we could extract, not that the figure is zero. Penalty and disgorgement are stored separately so aggregates across the library do not double-count the same dollars. This regulator states penalties in INR. The figure is recorded as published and is not converted, so it does not appear in the USD totals or medians used elsewhere on this site.

What is alleged to have happened

A SEBI adjudicating officer issued this order on 11 August 2023. It covers Concord Drugs Ltd, listed on BSE, and eleven current or former officers: the chairman, the managing director, the chief financial officer, four directors treated as non-independent and four successive compliance officers. The period examined was FY2015-16 to FY2019-20.

SEBI acted on a complaint about differences in the company's trade receivables. On review, it noticed invoices carrying manufacturing dates later than the invoice dates, mismatched debtor names and addresses, and shared addresses among debtors. It referred these to BSE for a forensic audit, and SEBI then opened an investigation in April 2022. SEBI alleged that the company misrepresented its accounts, left out related parties and their transactions, and failed to obtain required approvals.

The order finds the company misrepresented its accounts through wrong statements, disclosures and omissions, did not follow accounting standards, appointed ineligible independent directors, did not file a limited review report, and twice went without a compliance officer. It held that these lapses together enabled the company to present a false positive picture to investors, which it treated as fraud on the market, in breach of section 12A of the SEBI Act, Regulations 3 and 4 of the PFUTP Regulations and the listing regulations. The chairman, managing director, CFO and four directors were held responsible; the four compliance officers were held to have breached Regulation 6 of the listing regulations.

Penalties were set per noticee: Rs 15,00,000 each on the company, the chairman and the CFO; Rs 16,00,000 on the managing director; Rs 10,00,000 each on two directors; Rs 11,00,000 each on two other directors; and Rs 1,00,000 each on the four compliance officers. Together these come to Rs 1,07,00,000, the figure recorded here. Some of the amounts cover several provisions at once, so the order's table, not this total, governs each person's liability.

The record does not show whether any noticee appealed, whether the invoices were found to be fabricated in a criminal sense, or any investor loss. It mentions no criminal case.

This library tags the matter as misleading issuer disclosure. The tagging is ours, not the regulator's.

For the regulator's own account of the facts, read the primary document linked above. This page deliberately summarises the structured record rather than reproducing the order.

What technique is this, and how does it work?

This action is tagged with one technique in our taxonomy. The tagging is ours: regulators charge statutory provisions, not technique names, so the mapping is an editorial judgement described in our editorial policy.

• Misleading issuer disclosure — see how it works, what statute it engages, and every other action tagged the same way.

Timeline

1. 2023-08-11 SEBI order

Primary documents

Everything on this page derives from the documents below. Where our summary and the primary document disagree, the primary document is right.

• SEBI order

The linked release is published by the issuing regulator under its own terms. Our summary and narrative above are our own writing.

Related actions

Other actions in the library sharing at least one technique tag with this one.

Record added October 8, 2026. submit a correction.